Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call and Business Update

Download as PDF

Conference call to take place May 9th, 2018 at 8:30am E.T.

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals (NYSE MKT: NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Wednesday, May 9, 2018 at 8:30am E.T. to discuss its financial results for the first quarter of 2018, in conjunction with the filing of its quarterly report on Form 10-Q for the first quarter ended March 31, 2018.

Michael Goldberg, President and Chief Executive Officer, and Jed Latkin, Chief Financial and Operating Officer of Navidea, will host the call and provide an update on recent developments and clinical progress. Management will be answering questions live immediately following the earnings announcement part of the call.

To participate in the call, please dial +1 929-477-0448 in the U.S. and Canada. The conference ID number is 9493945.

 
Event: Q1 2018 Earnings and Business Update Conference Call
Date: Wednesday, May 9th, 2018
Time: 8:30am E.T.
U.S. & Canada Dial-in: +1 929-477-0448
Conference ID: 9493945
Webcast Link:

http://www.audio-webcast.com/cgi-bin/visitors.ssp?fn=visitor&id=5603

 

A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.

For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals, Inc.
Jed Latkin, 614-973-7490
CFO/COO
jlatkin@navidea.com
or
Edison Advisors
Tirth Patel, 646-653-7035
tpatel@edisongroup.com

Source: Navidea Biopharmaceuticals

Released May 2, 2018